Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).
C ProtoM GanzinelliS ManglavitiM ImbimboG GalliM MarabeseF ZolloM F AlvisiM PerrinoN CorduaF BoreaF de VincenzoA ChellaS CappelliE PardiniZ BallatoreA LucarelliE AmbrosiniM GiulianoE PietroluongoC MulargiuA FabbriA PrelajM OcchipintiM BrambillaL MazzeoT BeninatoR VigoritoM RuggirelloF G GrecoG CalaresoD MilizianoE RulliI De SimoneV TorriF G M de BraudG PaselloP De PlacidoR BerardiI PetriniP ZucaliM C GarassinoG Lo RussoPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
In previously untreated advanced TC, the addition of ramucirumab to carboplatin and paclitaxel showed the highest activity compared to historical controls, with a manageable safety profile. Despite the small number of patients, given the rarity of the disease, the trial results support the consideration of this combination as first-line treatment in TC.